Company: RGBP
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012619
Chunk: 6

Company: Regen BioPharma Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
 revenue from licensees for contractual obligations such as License
Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned
by the Company.

J. RESEARCH AND DEVELOPMENT COST

Research
and development (R& D) costs are expensed as incurred. R& D costs are related to the Company’s internally funded development
of the Company’s product developments and patents. The Company R& D costs were $ 0 40,133

K. FAIR VALUE MEASUREMENT

The
estimated fair values of financial instruments reported in the consolidated financial statements have been determined using available
market information and valuation methodologies, as applicable. The fair value of cash due to its short maturity is classified as a Level 1

Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
Entities are required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value
based upon the following fair value hierarchy:

  Level 1 —      Quoted prices in active markets for identical assets or liabilities;                                                                                                                                  
  Level 2 —      Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be...  
  Level 3 —      Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.                                                       

As
of March 31, 2025,

SCHEDULE
OF FAIR VALUE HIERARCHY MEASURED AT RECURRING BASIS

                                             Level 1      Level 2      Level 3  
  Investment Securities (Related Party)                                $17,733  
 ────────────────────────────────────────────────────────────────────────────────

As
of September 30, 2024,

                                             Level 1      Level 2      Level 3  
  Investment Securities (Related Party)                                $17,733  
 ────────────────────────────────────────────────────────────────────────────────

L. STOCK-BASED COMPENSATION

The
Company accounts for share-based compensation in accordance with the fair value recognition provisions of FASB ASC Topic 718, Share-based
Payment, which requires all share-based payments to employees